Volume 24 - Issue 5 - May 2016
Department
SDPA Feature
05/24/2016
PAs have a responsibility to advocate for their profession. This article offers recommendations on how PAs can get involved at the local, state, and national levels.
PAs have a responsibility to advocate for their profession. This article offers recommendations on how PAs can get involved at the local, state, and national levels.
PAs have a responsibility to...
05/24/2016
The Dermatologist
Research in Review
05/23/2016
New psoriasis therapies have increased the ability for patients to achieve skin clearance. However, more evidence is needed on the impact of total skin clearance from the patient perspective.
Researchers set out to determine if complete skin...
New psoriasis therapies have increased the ability for patients to achieve skin clearance. However, more evidence is needed on the impact of total skin clearance from the patient perspective.
Researchers set out to determine if complete skin...
New psoriasis therapies have...
05/23/2016
The Dermatologist
News
News
05/23/2016
IntraDerm Pharmaceuticals’ Ceramax skin barrier cream recently received FDA clearance as a topical skincare preparation to relieve and to manage the burning and itching associated with various dermatoses.
IntraDerm Pharmaceuticals’ Ceramax skin barrier cream recently received FDA clearance as a topical skincare preparation to relieve and to manage the burning and itching associated with various dermatoses.
IntraDerm Pharmaceuticals’...
05/23/2016
The Dermatologist
News
05/23/2016
The open-label extension (OLE) study evaluated the long-term safety and efficacy of etanercept (Enbrel) for pediatric psoriasis.
The open-label extension (OLE) study evaluated the long-term safety and efficacy of etanercept (Enbrel) for pediatric psoriasis.
The open-label extension (OLE)...
05/23/2016
The Dermatologist
News
05/20/2016
The Corrona Psoriasis Registry will track the drug safety reporting for ixekizumab (Taltz), a new biologic medication by Eli Lilly and Company that was recently FDA approved for the treatment of moderate to severe plaque psoriasis.
The Corrona Psoriasis Registry will track the drug safety reporting for ixekizumab (Taltz), a new biologic medication by Eli Lilly and Company that was recently FDA approved for the treatment of moderate to severe plaque psoriasis.
The Corrona Psoriasis Registry...
05/20/2016
The Dermatologist
Column
Chief Medical Editor Message
05/23/2016
In recent years, the field of economics has been invigorated with the work of experimental behavioral psychologists.
In recent years, the field of economics has been invigorated with the work of experimental behavioral psychologists.
In recent years, the field of...
05/23/2016
The Dermatologist
